Zymeworks to Present at Jefferies Virtual Healthcare Conference
May 26 2021 - 8:30AM
Business Wire
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical
company developing multifunctional biotherapeutics, today announced
that the Company will present at the upcoming Jefferies Virtual
Healthcare Conference taking place June 1-4, 2021.
The Company’s presentation will be on Thursday, June 3, 2021 at
10:00 a.m. ET.
Interested parties can access a live webcast of the presentation
via a link from Zymeworks’ website at
http://ir.zymeworks.com/events-and-presentations, which will also
host a recorded replay available afterwards.
About Zymeworks Inc.
Zymeworks is a clinical-stage biopharmaceutical company
dedicated to the development of next-generation multifunctional
biotherapeutics. Zymeworks’ suite of therapeutic platforms and its
fully integrated drug development engine enable precise engineering
of highly differentiated product candidates. Zymeworks’ lead
clinical candidate, zanidatamab (ZW25), is a novel Azymetric™
bispecific antibody which has been granted Breakthrough Therapy
designation by the FDA and is currently enrolling in a pivotal
clinical trial for refractory HER2-amplified biliary tract cancer
(HERIZON-BTC-01) as well as several Phase 2 clinical trials for
HER2-expressing gastroesophageal and breast cancers. Zymeworks’
second clinical candidate, ZW49, is a novel bispecific
HER2-targeting antibody-drug conjugate currently in Phase 1
clinical development and combines the unique design and antibody
framework of zanidatamab with Zymeworks’ proprietary ZymeLink™
linker and cytotoxin. Zymeworks is also advancing a deep
preclinical pipeline in oncology (including immuno-oncology agents)
and other therapeutic areas. In addition, its therapeutic platforms
are being leveraged through strategic partnerships with nine
biopharmaceutical companies. For additional information about
Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on
Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210526005145/en/
Investor Inquiries: Ryan Dercho, Ph.D. (604) 678-1388
ir@zymeworks.com Jack Spinks (604) 678-1388 ir@zymeworks.com Media
Inquiries: Mary Klem (604) 678-1388 media@zymeworks.com
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Apr 2023 to Apr 2024